Economic Burden of ANCA-Associated Vasculitis in the USA Save
To assess the prevalence and magnitude of healthcare costs associated with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in the USA, researchers analyzed adminstrative data from Truven Health MarketScan Commercial and Medicare Supplemental databases. Major relapses (using the Birmingham Vasculitis Activity Score) and healthcare costs were assessed during a 24-month followup period.
A total of 2784 patients with GPA were found and 18.7% experienced a major relapse in the 12-month followup period. Those with relapses incurred higher overall costs (12-month: $88,065 vs $30,682; p 0.0001) and GPA-related costs (12-month: $61,636 vs $15,748; p 0.0001) than patients without a relapse. Of the 612 incident patients with MPA, healthcare costs nearly doubled ($30,166 vs $56,642; p 0.0001).
Overall the diagnosis of MPA doubled the cost of care, and a relapse of GPA resulted in a 3-4 fold increase in healthcare costs.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.